{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Acetate&page=2", "query": { "intervention": "Abiraterone Acetate", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Acetate&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Acetate&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T15:03:10.992Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00638690", "title": "Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1195, "start_date": "2008-05", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-04-30", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638690" }, { "nct_id": "NCT01897389", "title": "A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Treatment A", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Treatment D", "type": "DRUG" }, { "name": "Treatment E", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 32, "start_date": "2013-07", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-02", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897389" }, { "nct_id": "NCT04104893", "title": "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2020-02-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 13, "location_summary": "San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104893" }, { "nct_id": "NCT07611110", "title": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Deutenzalutamide", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 670, "start_date": "2026-05-04", "completion_date": "2030-06-06", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 26, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07611110" }, { "nct_id": "NCT02737332", "title": "A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Zytiga® (Abiraterone Acetate)", "type": "DRUG" }, { "name": "SoluMatrix™ (Abiraterone Acetate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 53, "start_date": "2016-03-21", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 17, "location_summary": "Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02737332" }, { "nct_id": "NCT03833921", "title": "Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic", "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Martha Mims", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 130, "start_date": "2019-05-23", "completion_date": "2038-04", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833921" }, { "nct_id": "NCT05367440", "title": "Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "AZD5305", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 174, "start_date": "2022-06-02", "completion_date": "2031-04-11", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 6, "location_summary": "Detroit, Michigan • Syracuse, New York • Myrtle Beach, South Carolina + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Syracuse", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05367440" }, { "nct_id": "NCT02456571", "title": "CTC Immune Checkpoint", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CTC biomarker expression prevalence", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 38, "start_date": "2016-11", "completion_date": "2019-06-13", "has_results": false, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02456571" }, { "nct_id": "NCT03012321", "title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic Castration-Resistant", "Abnormal DNA Repair", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 70, "start_date": "2017-01-12", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 16, "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012321" }, { "nct_id": "NCT01715259", "title": "A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Insufficiency" ], "interventions": [ { "name": "Abiraterone acetate: participants with end-stage renal disease", "type": "DRUG" }, { "name": "Abiraterone acetate: matched control participants with normal renal function", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "40 Years to 80 Years · Male only" }, "enrollment_count": 16, "start_date": "2009-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-11-19", "last_synced_at": "2026-09-30T15:03:10.992Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01715259" } ] }